Kelly CM - Search Results

1

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

Andreopoulou E, Kelly CM, McDaid HM. Andreopoulou E, et al. Among authors: kelly cm. Breast Care (Basel). 2017 Mar;12(1):21-28. doi: 10.1159/000455821. Epub 2017 Feb 7. Breast Care (Basel). 2017. PMID: 28611537 Free PMC article. Review.

2

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Kelly CM, et al. Ann Oncol. 2011 Nov;22(11):2387-2393. doi: 10.1093/annonc/mdq786. Epub 2011 Mar 15. Ann Oncol. 2011. PMID: 21406473 Free article.

3

Overview of recent advances in metastatic triple negative breast cancer.

O'Reilly D, Sendi MA, Kelly CM. O'Reilly D, et al. Among authors: kelly cm. World J Clin Oncol. 2021 Mar 24;12(3):164-182. doi: 10.5306/wjco.v12.i3.164. World J Clin Oncol. 2021. PMID: 33767972 Free PMC article. Review.

4

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

O'Sullivan Coyne G, Walsh J, Kelly CM. O'Sullivan Coyne G, et al. Among authors: kelly cm. Expert Opin Drug Saf. 2012 Jul;11(4):643-50. doi: 10.1517/14740338.2012.698608. Epub 2012 Jun 14. Expert Opin Drug Saf. 2012. PMID: 22694309

5

Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.

Kelly CM, Buzdar AU. Kelly CM, et al. Drugs. 2013 May;73(6):505-15. doi: 10.1007/s40265-013-0044-0. Drugs. 2013. PMID: 23605692 Review.

6

Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Iwamoto T, Kelly C, Mizoo T, Nogami T, Motoki T, Shien T, Taira N, Hayashi N, Niikura N, Fujiwara T, Doihara H, Matsuoka J. Iwamoto T, et al. Clin Breast Cancer. 2016 Apr;16(2):95-100.e1. doi: 10.1016/j.clbc.2015.10.004. Epub 2015 Nov 10. Clin Breast Cancer. 2016. PMID: 26631838

7

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L. Santarpia L, et al. Among authors: kelly cm. Oncologist. 2016 Sep;21(9):1063-78. doi: 10.1634/theoncologist.2015-0369. Epub 2016 Jul 6. Oncologist. 2016. PMID: 27384237 Free PMC article. Review.

8

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT. Toomey S, et al. Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9. Breast Cancer Res. 2017. PMID: 28750640 Free PMC article. Clinical Trial.

9

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Traina TA, et al. J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373071 Free PMC article. Clinical Trial.

10

Oligometastatic breast cancer: Are we there yet?

AlSendi M, O'Reilly D, Zeidan YH, Kelly CM. AlSendi M, et al. Among authors: kelly cm. Int J Cancer. 2021 Oct 15;149(8):1520-1528. doi: 10.1002/ijc.33693. Epub 2021 Jun 8. Int J Cancer. 2021. PMID: 34013530 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

337 results

Search Page